Enterprise Value
318.6M
Cash
597M
Avg Qtr Burn
-16.09M
Short % of Float
9.63%
Insider Ownership
27.21%
Institutional Own.
52.86%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Safusidenib [mIDH1 inhibitor] Details Cancer, High-grade Glioma
| Phase 2 Data readout | |
Taletrectinib (ROS1 inhibitor) Details Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
NUV-1511 Details Solid tumor/s | Phase 1/2 Data readout | |
NUV-868 +olaparib Details Solid tumor/s, Cancer, Pancreatic cancer, Ovarian cancer, Castration-resistant prostate cancer, Triple-negative breast cancer | Phase 1b Data readout | |
NUV-868 +enzalutamide Details Cancer, Solid tumor/s, Castration-resistant prostate cancer | Phase 1b Data readout | |
NUV-868 (BD2-Selective BETi) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
NUV-422 (CDK inhibitor) Details High-grade Glioma
, Solid tumor/s, Cancer, Prostate cancer, Breast cancer, Castration-resistant prostate cancer, Metastatic breast cancer | Failed Discontinued |